Main Menu
Menu

Blog

Publish Date
BlogFact Checks
Fact Check: What Critics Get Wrong About the Patent Eligibility Restoration Act

A coalition of anti-patent groups — including the R Street Institute, the Electronic Frontier Foundation, Public Knowledge, and others — recently sent...

Blog
C4IP Coalition Updates: November 2025

November Highlights: The Upcoming Review of the USMCA This fall marked the beginning of the first scheduled Joint Review process for the...

Blog
This Month in IP: November 2025

Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From gardening...

BlogFact Checks
Fact Check: Weakening the patent system won’t lower prices for patients. It would undermine medical progress.

In a recent STAT article, I-MAK CEO Tahir Amin argues that abuses of the patent system are leading to higher drug costs....

Blog
Inventor Spotlight: Ronald Rivest, Adi Shamir, and Leonard Adleman

C4IP is honoring Ronald Rivest (born 1947), Adi Shamir (b. 1952), and Leonard Adleman (b. 1945), whose invention of RSA cryptography forms...

BlogFact Checks
Fact Check: The Data Doesn’t Support the Existence of So-Called Patent “Thickets”

Several academic authors recently published an article in Health Affairs Forefront advising policymakers in Congress and at the USPTO on the best...

Blog
‘Tis the Season — of Counterfeits?

Counterfeiting is a multi-billion-dollar enterprise that puts consumers at serious risk. Poorly-made laptop batteries can overheat. Knock-off cosmetics may contain toxic chemicals....

Blog
This Month in IP: October 2025

Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From firefighting...

Blog
C4IP Coalition Updates: October 2025

October Highlights: C4IP Advocates for the Patent Eligibility Restoration Act On October 8, the Senate Judiciary Subcommittee on Intellectual Property held a...

Blog
Why Continued Innovation Matters: Keytruda and the “Product Hopping” Myth

The FDA recently approved a new version of Keytruda, a cancer immunotherapy medicine that is one of the world’s most successful drugs....

BlogFact Checks
Fact Check: The Myth of So-Called “Royalty Free” and “Open” Standards

The word “open” has become increasingly misused in the world of technology standards. In policy and antitrust terms, an open standard is...

Blog
Highlights from the October 8 PERA Hearing

On October 8, the Senate Judiciary Subcommittee on Intellectual Property held a hearing on the Patent Eligibility Restoration Act (PERA) to examine...

Op-Eds:

Blog, Op-Eds:

Europe Stands at a Crossroads on Technology Policy,

01/24/2024
Blog:

Blog:

Celebrating American Innovation: Ashok Gadgil,

01/18/2024
Op-Eds:

Blog, Op-Eds:

President Biden’s domestic technology seizure plan,

01/14/2024
Op-Eds:

Blog, Op-Eds:

Blame Washington for Drug Shortages,

01/05/2024
Blog:

Blog:

This Month in IP: The Impact of the Bayh-Dole Act,

01/02/2024
Blog:

Blog:

C4IP Coalition Updates: December 2023,

12/21/2023
Blog:

Blog, Fact Checks:

Fact Check: The PREVAIL Act Would Not Protect “Bad” Patents,

12/20/2023
Blog:

Blog:

Celebrating American Innovation: Lloyd Hall,

12/18/2023
Op-Eds:

Blog, Op-Eds:

Innovators Need Patent Reform Now,

12/11/2023
Blog:

Blog:

C4IP Co-Chair Andrei Iancu Moderates Innovation Policy Panel with Rep. Deborah Ross (D-NC),

12/07/2023
Blog:

Blog:

C4IP Coalition Updates: November 2023,

12/06/2023
Blog:

Blog:

This Month in IP: November 2023,

12/05/2023
Scroll to Top